MBX Biosciences, Inc.

For the period ended Sep 30, 2026. Filed Nov 9, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 9, 2026

MBX$54.06+5.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Other Information

Item 5. Other Information.

(c) During thethree months ended September 30, 2026, none of our directors or “officers,” as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, adopted orterminated a Rule 10b5-1 trading plan or arrangement or a non-Rule 10b5-1 trading plan or arrangement, as defined in Item 408(c) of Regulation S-K, except as follows:

Name	Title	Reporting Action	Plan Start Date	Plan End Date	Maximum number of Shares of Common Stock to be Sold	Intended to Satisfy Rule 10b5-1(c)?
Salomon Azoulay	Chief Medical Officer	Plan Adoption	July 15, 2026	January 15, 2027	113,626	Yes

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.